GWPRF - GW Pharmaceuticals plc

Other OTC - Other OTC Delayed Price. Currency in USD
-0.35 (-3.18%)
At close: 3:43PM EDT
Stock chart is not supported by your current browser
Previous Close11.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range10.65 - 11.00
52 Week Range7.07 - 16.00
Avg. Volume3,211
Market Cap3.947B
Beta (3Y Monthly)2.11
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Medical Cannabis: A Hot Topic at Events Across the World
    Market Realist

    Medical Cannabis: A Hot Topic at Events Across the World

    These days, experts are discussing the pros and cons of medical cannabis at multiple conferences and summits around the world.

  • Is the U.S. Getting on Board With Cannabis Legalization?
    Motley Fool

    Is the U.S. Getting on Board With Cannabis Legalization?

    Here's what to expect from a government agency that's listening to what people have to say about marijuana legalization.

  • 5 of the Most Cash-Rich Cannabis Stocks
    Motley Fool

    5 of the Most Cash-Rich Cannabis Stocks

    You could rightly say that these five pot stocks are swimming with green.

  • Benzinga

    UK NHS Says Epidiolex Too Expensive, GW Pharma Says Company 'Remains Hopeful'

    GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH )'s CBD drug Epidiolex, which treats epilepsy, has been deemed too expensive by the U.K.’s National Health Service, according to an  iNEWS report. Epidiolex has ...

  • 5 Ways to Invest in the Marijuana Craze With Ancillary Stocks
    Motley Fool

    5 Ways to Invest in the Marijuana Craze With Ancillary Stocks

    You don't have to buy cannabis growers or pot retailers to make money in the marijuana space.

  • Is GW Pharmaceuticals a Buy?
    Motley Fool

    Is GW Pharmaceuticals a Buy?

    To buy or not to buy? That's the question for GW Pharmaceuticals. And here's the answer.

  • Better Buy: GW Pharmaceuticals vs. Amarin
    Motley Fool

    Better Buy: GW Pharmaceuticals vs. Amarin

    Two mid-cap biotechs. Two tremendously successful drugs already on the market. But which is the better long-term stock pick?

  • Benzinga

    Early Success Of CBD Drug Looms Large For The Industry's Future

    Last week, GW Pharmaceuticals (NASDAQ: GWPH) released its financial results for the second quarter, and the results surprised analysts and investors alike. Year-over-year, the company's revenue for the quarter rose from $3.3 million to $72 million, an increase of 20.8x. Most of that revenue came from sales of the company's flagship drug, cannabidiol (CBD)-derived Epidiolex, which reached $68.4 million for the quarter and $101.9 million for the first half of the year, destroying even the most bullish of industry predictions.

  • 3 Cannabis Stocks With the Fastest-Growing Sales
    Motley Fool

    3 Cannabis Stocks With the Fastest-Growing Sales

    These cannabis stocks boast sizzling sales growth. But are they great picks for investors to buy now?

  • Weekly Cannabis Stock News: GW Pharmaceuticals Blows Past Estimates
    Motley Fool

    Weekly Cannabis Stock News: GW Pharmaceuticals Blows Past Estimates

    Quarterly results, more quarterly results, a new buyout and a potentially new Nasdaq marijuana stock -- last week was far from boring in the cannabis industry.

  • Benzinga

    The Week In Cannabis: CannTrust Rallies Unexpectedly, Josh Kushner And Shane Victorino Join The Industry, And More

    TerrAscend is a portfolio company of Canopy Rivers Inc (OTC: CNPOF), the investment arm of Canopy Growth Corp (NYSE: CGC). Arcadia Biosciences (NASDAQ: RKDA) announced a hemp products joint venture, Archipelago Ventures, involving Shane Victorino, a former MLB player and son of Maui Mayor Mike Victorino.

  • Marijuana-derived epilepsy drug doubles sales, sending GW Pharma stock soaring

    Marijuana-derived epilepsy drug doubles sales, sending GW Pharma stock soaring

    GW Pharmaceuticals PLC reported Tuesday afternoon that sales of its cannabis-derived epilepsy drug more than doubled from the previous quarter, sending shares spiking more than 11% higher in after-hours trading.

  • GW Pharmaceuticals (GWPH) Q2 2019 Earnings Call Transcript
    Motley Fool

    GW Pharmaceuticals (GWPH) Q2 2019 Earnings Call Transcript

    GWPH earnings call for the period ending June 30, 2019.

  • Motley Fool

    Cronos Group's Q2 Trounces Estimates

    The cannabis company more than triples its revenue figure.

  • Benzinga

    Cramer: Epidiolex Maker GW Pharma Is Far From A 'Sketchy' Weed Business

    CEO Justin Gover told Cramer during an interview on "Mad Money" he agrees with Cramer's assessment of GW Pharmaceuticals — and all he can do is continue focusing on the company's core medicine and pipeline.

  • 6 Positive Catalysts to Drive GW Pharmaceuticals (GWPH) Stock Further

    6 Positive Catalysts to Drive GW Pharmaceuticals (GWPH) Stock Further

    The good news for GW Pharmaceuticals (GWPH) was it generated a profit in its latest reporting period. The bad news is it was the result of a $104.1 million one-off sale of its Rare Pediatric Priority Review Voucher in the quarter. The better news is its core product Epidiolex significantly exceeded sales expectations, and should retain growth trajectory going forward.In this article we'll look at six reasons GW Pharmaceuticals should continue to find support, even though it's certain it'll have a loss in its next reporting period; albeit the losses should continue to narrow. It's probably not too long before the company starts to produce a sustainable profit.Positive Catalysts for EpidiolexThe first three of the six reasons to like GW Pharmaceuticals in the future are associated with its flagship product Epidiolex, which accounted all but $3.6 million in revenue for the quarter.First, sales of Epidiolex wildly exceeded expectations, as it had net sales of $68.4 million in the second quarter, far above the $47 million analysts on average were looking for. Total company sales in the quarter came in at $72 million.Next, health care prescribing by health care providers has been increasing, with over 12,000 patients now having used the treatment since it launched in 2018. At this time over 2,500 physicians have prescribed Epidiolex, with the vast majority of them continuing using the therapy, according to Chief Executive Justin Glover.Last, private and public payers don't appear to have any qualms about covering Epidiolex, with approximately 93 percent of them covering it in the U.S. market.That suggests sustainable performance in the quarters ahead, although the pace of that growth may not be what it was in the last quarter.Probable New Treatments for EpidiolexI put this 4th reason to like GW Pharma into a separate category because it points to future potential and not the existing use of Epidiolex. It's highly probable that the company will gain approval for using the drug in Europe, but that has yet to be confirmed.GW Pharmaceuticals is awaiting the approval of the EU for using Epidiolex to treat Lennox-Gastaut syndrome (LGS) and Dravet syndrome in the early part of October.It would be surprising if the company didn't receive approval, and its fairly safe to at least this will be another revenue stream for the company.Assuming approval, it would launch first in the two largest European markets, Germany in France, with the goal of doing so some time in the fourth quarter. After that it'll launch in Italy and Spain in 2020.More speculative is its research on how Epidiolex may be effective on treating Rett syndrome. It has plans to launch a clinical study to determine if Sativex can be used to treat spasticity in multiple sclerosis patients. The goal there is to obtain approval to use the treatment in the U.S.Finally, it has started to look at recruiting participants in a study that will determine if cannabidivarin can effectively treat autism.Most important here is GW Pharmaceuticals is working on building out a pipeline that would generate meaningful long-term growth for the company, if a number of them are cleared to treat patients. This would significantly increase it patient base, revenue and earnings.Solid Balance Sheet and Cash PositionInvestors should understand that even with all the positive sentiment surrounding GW Pharmaceuticals, it's still going to burn through a lot of cash as it ramps up research and expands to other markets.In the near future it's not going to have another one-time sale of an asset to offset the spending in its earnings results.That could be extremely detrimental to a number of weaker cannabis companies, but GW Pharma has under $30 million in long-term liabilities at this time, and a lot of cash on hand to keep the company from having to issue equity to raise capital, which would dilute existing shareholders' shares.At the end of the reporting period GW had cash and cash equivalents of $583.7 million. That's only about $8 million less than it had at the end of calendar year 2018.The company should obtain some approvals in the near future, and that will generate more revenue and earnings to bolster its balance sheet. It won't immediately catch up with spending, but it does show a path to profitability that it can obtain with probably little need to increase its share count.So the fifth thing to like about GW is it has a strong balance sheet and cash on hand to spend on research and growth without diluting its shares.Analysts Still Bullish on the CompanyThe sixth reason to like GW in the future is it still attracts a lot of bullish sentiment from analysts.Both Oppenheimer and Stifel Nicolaus raised their price targets on GW, with Bank of America/Merrill Lynch retaining its 'buy' rating on the stock.Oppenheimer raised its one-year price target from $234 to $239, and Stifel Nicolaus boosted its one-year price target from $227 to $228.Overall, TipRanks reveals that GWPH has a Strong Buy analyst consensus rating with 5 back-to-back 'buy' ratings in the last three months. Meanwhile the average analyst price target of $221.80 suggests the stock has upside potential of just over 30% from the current share price for the next 12 months. (See GWPH's price targets and analyst ratings on TipRanks)Although I don't make my long-term investment decisions on the outlook and estimates of analysts, many investors do, and in the case of boosting their bullish case for a stock, usually provides a higher floor and ceiling.Combined with the other positive catalysts above, it should provide further upward trajectory for the share price of the stock, assuming GW doesn't drop the ball in some way.ConclusionThere is a lot to like about GW Pharmaceuticals, especially the future potential of Epidiolex and other potential treatments in its pipeline, which will without a doubt generate significant revenue if they're approved, And as mentioned above, some of the less speculative are close to certain to being approved in the EU, which will open up another revenue stream.With the overall health complex in the U.S. having a positive response to Epidiolex at various touch points, this is going to be an ongoing growth engine for GW; investors will probably need to lower expectations on future growth trajectory, even though the company surprised so strongly on the revenue side in the latest quarter.I don't believe it has reached an incremental growth stage yet, but eventually it will. By that time it should have other markets to sell into, partially offsetting the slowing sales trajectory in the U.S. in the future. That time isn't here yet, but it's not a long way off. It could happen within a year in the U.S. market.The pace and timing will be determined on how consumers think concerning moving away from competitive drugs into the perceived safety of Epidiolex. If it gains more U.S. market share, its growth trajectory could last longer than I'm expecting as the company stands today.With a strong balance sheet and cash position, along with the potential to grow out its product pipeline in new markets and treatments, the long-term future of GW Pharmaceuticals looks very profitable for those in it for the long haul.GW Pharmaceuticals boasts an 8 score from TipRanks Smart Score. That’s thanks to a combination of bullish datapoints, including a ‘Strong Buy’ consensus from the Street, bullish blogger opinions, and even positive sentiment from investors. (More details here)

  • The Rally in GW Pharmaceuticals Should Continue - Here's How I'd Play It

    The Rally in GW Pharmaceuticals Should Continue - Here's How I'd Play It

    In his second "Executive Decision" segment of Mad Money Wednesday night, Jim Cramer spoke with Justin Gover, CEO of GW Pharmaceuticals plc , the medical cannabis provider with shares that soared 9.1% Wednesday after the company posted earnings of 21 cents a share, when analysts were expecting it to only break even. Gover said that over the past six months, more than 12,000 patients have received prescriptions for Epidiolex, GWPH's anti-seizure medication. Gover said there is still much education to be done with physicians, letting them know what Epidiolex is and how it works for their patients suffering with seizures.

  • Motley Fool

    3 Pot Stocks With Rising Profit Projections

    Although most cannabis stock earnings estimates are falling, these companies are bucking the trend.

  • Benzinga

    GW Pharma Analysts Raise Estimates After CBD Drug Epidiolex Shows Strong Uptake

    Morgan Stanley analyst David Lebowitz maintained an Overweight rating on GW Pharma and increased the price target from $234 to $238. GW Pharma's CBD epilepsy medication Epidiolex saw strong sales of $68 million in its second full quarter on the U.S. market compared to the consensus estimate of $45 million, with 12,000 patients having received the therapy and a majority of them staying with the medication, Lebowitz said in a Wednesday note.

  • GW Pharmaceuticals Q2 Results Crush Revenue Estimates; Stock Soars
    Motley Fool

    GW Pharmaceuticals Q2 Results Crush Revenue Estimates; Stock Soars

    The company's fundamentals got a major boost from its star drug, Epidiolex.

  • Benzinga

    The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 6) Allakos Inc (NASDAQ: ALLK )(announced common stock offering) ...


    [video]GW Pharma Surges on Marijuana-Based Epilepsy Drug Sales, Analyst Upgrades

    Shares of GW Pharmaceuticals surge following soaring sales of its marijuana-derived epilepsy drug that prompts two analysts to raise their stock-price targets.

  • 3 Things You'll Want to Know About GW Pharmaceuticals' Sizzling Q2 Results
    Motley Fool

    3 Things You'll Want to Know About GW Pharmaceuticals' Sizzling Q2 Results

    Fast-growing CBD drug sales powered yet another tremendous quarter for the cannabis-focused biotech.

  • Biotech Stock Pops Higher Alongside Demand For Cannabis Medicine
    Investor's Business Daily

    Biotech Stock Pops Higher Alongside Demand For Cannabis Medicine

    GW Pharmaceuticals stock rocketed late Tuesday after the biotech company announced sales of its cannabis medicine, Epidiolex, crushed the Street's estimates in the second quarter.

  • Benzinga

    GW Pharma Rallies On Strong Q2 Epidiolex Sales, Says European Approval Expected In October

    GW Pharma posted $72 million in revenue in the quarter versus $3.3 million in the same period last year. Epidiolex has been prescribed to more than 12,000 patients since its launch, the company said. Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 — click here to learn more!